June 19, 2010

Exalenz shares soar on liver trial results: Early diagnosis of cirrhosis is important, because it greatly improves treatment

6/13/10 - Exalenz Bioscience Ltd. (TASE:EXEN) has successfully completed the feasibility study to test the effectiveness of its BreathID device to diagnose the severity of liver disease in people with Hepatitis B. The trial was carried out at the Prince of Wales University Hospital in Hong Kong.

Exalenz's share price rose 12.6 percent by midday today to NIS 0.95, giving a market cap of NIS 102 million.

The trial included 47 patients. The BreathID device was able to distinguish between patients in early stages of cirrhosis of the liver and patients with late-stage cirrhosis with an accuracy of 91 percent. Early diagnosis of cirrhosis is important, because it greatly improves treatment and the patients and medical teams' ability to deal with the disease.

The company intends to expand the study to 100 patients, in order to demonstrate the effectiveness of the BreathID device in predicting clinical results.

The BreathID system can assess a range of liver and gastrointestinal disorders by molecular analysis of patients' exhaled breath. It uses a laser-like light source to pinpoint real-time changes in carbon 13-carbon 12 isotope ratios at an accuracy level of single parts per million.

Exalenz cautioned that the test results are insufficient to know whether it can commercialize the BreathID device in the US, Asia, or anywhere else. Commercialization will be dependent on successful clinical trials and the obtaining of regulator permits.

http://www.pharmacychoice.com/News/article.cfm?Article_ID=591824

No comments:

Post a Comment